



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## GDC-2394

Cat. No.:	HY-148258		
CAS No.:	2238822-07-4		
Molecular Formula:	C <sub>20</sub> H <sub>25</sub> N <sub>5</sub> O <sub>4</sub> S		
Molecular Weight:	431.51		
Target:	Interleukin Related; Caspase; NOD-like Receptor (NLR)		
Pathway:	Immunology/Inflammation; Apoptosis		
Storage:	Powder	-20°C	3 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

In Vitro	DMSO : 50 mg/mL (115.87 mM; ultrasonic and warming and heat to 60°C)					
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
			1 mM	2.3174 mL	11.5872 mL	23.1744 mL
			5 mM	0.4635 mL	2.3174 mL	4.6349 mL
			10 mM	0.2317 mL	1.1587 mL	2.3174 mL
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (4.82 mM); Clear solution					
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (4.82 mM); Clear solution					
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (4.82 mM); Clear solution					

### BIOLOGICAL ACTIVITY

Description	GDC-2394 is an orally active and selective NLRP3 inhibitor, and also inhibits IL-1β with IC <sub>50</sub> s of 0.4 μM (human IL-1β) and 0.1 μM (mouse IL-1β). GDC-2394 inhibits NLRP3-induced caspase-1 activity without inhibiting NLRP3-dependent inflammasome activation <sup>[1][2]</sup> .
In Vitro	GDC-2394 (20 μM; 30 min) inhibits NLRP3-induced apoptosis associated speck-like protein containing CARD (ASC) speck formation in THP-1 cells <sup>[1]</sup> . GDC-2394 (1 nM-10 μM; 7 d) inhibits human macrophage IL-1β and IL-18 production after activation of the NLRP3 inflammasome <sup>[1]</sup> .

GDC-2394 (0-20  $\mu$ M; 30 min) inhibits NLRP3-dependent caspase-1 activation ( $IC_{50}$ =51 nM) in THP-1 cells, also inhibits NLRP3-dependent IL-1 $\beta$  release ( $IC_{50}$ =63 nM) and NLRC4-dependent IL-1 $\beta$  release ( $IC_{50}$ >20  $\mu$ M) in mouse bone marrow-derived macrophages (mBMDMs)<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### In Vivo

GDC-2394 (compound 20) (1 mg/kg, 10 mg/kg; p.o.; single dose) inhibits production of IL-1 $\beta$  in an acute mouse peritonitis model<sup>[1]</sup>.

GDC-2394 (25 mg/kg; once daily for 7 d) reduces paw swelling and pain in a functional rat model of gouty arthritis<sup>[1]</sup>.

Preclinical PK of GDC-2394<sup>[1]</sup>.

Species	Mouse	Rat	Dog	Cyno
CL <sub>p</sub> (mL/min/kg)	10.1	1.3	11.7	4.1
V <sub>ss</sub> (L/kg)	0.72	0.29	0.67	0.18
T <sub>1/2</sub> (h)	1.2	4.4	0.99	0.89
%F (1 mg/kg)	80	33	78	53

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Acute mouse peritonitis model <sup>[1]</sup>
Dosage:	1 mg/kg and 10 mg/kg
Administration:	Oral gavage; 2 h later treated with 1.25 $\mu$ g LPS (i.p.) followed by 1 mg monosodium urate crystals (i.p.) a further 2 h later.
Result:	Resulted in a dose-dependent decrease in peritoneal IL-1 $\beta$ concentrations after MSU treatment, and decreased the level of IL-1 $\beta$ by 66.8 and 81.3% at 1 and 10 mg/kg compared with the control.

Animal Model:	Functional rat model of gouty arthritis <sup>[1]</sup>
Dosage:	25 mg/kg
Administration:	Interventional injection; once daily for 7 days
Result:	Significantly inhibited knee swelling after 48 h.

## REFERENCES

[1]. McBride C, et al. Overcoming Preclinical Safety Obstacles to Discover (S)-N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-6-(methylamino)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide (GDC-2394): A Potent and Selective NLRP3 Inhibitor. J Med Chem. 2022 Oct 24.

[2]. Stafford, et al. Preparation of hexahydroindacenylcarbamoyldihydropyrazolooxazinesulfonamide derivatives and analogs for use as interleukin-1 activity inhibitors: World Intellectual Property Organization, WO2018136890[P]. 2018-07-26.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA